StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 8.5 %

OGEN opened at $0.38 on Tuesday. The stock has a market cap of $4.58 million, a price-to-earnings ratio of -0.05 and a beta of 0.40. The stock has a fifty day moving average price of $0.34 and a 200 day moving average price of $0.65. Oragenics has a 1 year low of $0.25 and a 1 year high of $6.42.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.